ArticleJournal of arrhythmia2026
Left Ventricular Global Longitudinal Strain Is Associated With Appropriate Therapies for Ventricular Arrhythmias Independent of Left Ventricular Ejection Fraction in Patients With Primary Prevention Defibrillators.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular ejection fraction (LVEF) has not demonstrated reliability in predicting ventricular arrhythmias or appropriate implantable cardioverter defibrillator (ICD) therapy (AICDt). Objective: To evaluate the association between left ventricular global longitudinal strain (GLS) and AICDt. Methods: One hundred seventy-eight consecutive patients who received ICD implants for primary prevention of sudden cardiac death from 1/16/2015 to 1/26/2022 were followed until 1st appropriate ICD therapy (AICDt) for a ventricular arrhythmia, death, or loss to follow-up. AICDt were physician adjudicated. Covariates included demographic variables (age, sex), clinical risk factors (LVEF, cardiac resynchronization therapy, coronary artery disease, anti-arrhythmic drug use, QRS duration), and variables from the DO-IT model (nonsustained ventricular tachycardia, atrial fibrillation, glomerular filtration rate, peripheral vascular disease, direct oral anticoagulant use, digoxin use, aldosterone antagonist use, and angiotensin converting enzyme inhibitor/angiotensin II receptor blocker use). Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI Results: Over a mean (standard deviation) follow up period of 5.09 (2.11) years, 44 of the 178 patients (79.77% male, 63.89 (12.89) years of age) in the final cohort experienced AICDt. In patients with coronary artery disease, GLS per 5% decrease (absolute value) was associated with AICDt independent of demographic variables (HR 2.16, CI Conclusion: Reduced GLS (absolute value) is an independent risk factor for AICDt in patients with coronary artery disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.